{
    "clinical_study": {
        "@rank": "152852", 
        "arm_group": [
            {
                "arm_group_label": "TMZ group", 
                "arm_group_type": "Active Comparator", 
                "description": "patients were treated with TMZ alone"
            }, 
            {
                "arm_group_label": "TMZ plus CDDP group", 
                "arm_group_type": "Experimental", 
                "description": "patients were treated with TMZ plus CDDP"
            }
        ], 
        "brief_summary": {
            "textblock": "Temozolomide is the standard adjuvant chemotherapy of newly-diagnosis malignant\n      gliomas.Cisplatin , a kind of chemotherapeutics, can enforce the anti-tumor effects of TMZ.\n      Up to now, the prognosis of recurrent gliomas is very pessimistic and the standard treatment\n      procedure has not been established yet.\n\n      The prospective,multicentre phase II clinical study is to evaluate the efficacy and safety\n      of TMZ and CDDP in patients with recurrent malignant gliomas"
        }, 
        "brief_title": "Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas", 
        "condition": "Malignant Gliomas", 
        "condition_browse": {
            "mesh_term": "Glioma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Age>=18 and <=70years old\n\n          -  Histological diagnosis of malignant gliomas(WHO III or IV)\n\n          -  The status of methylation of promotor of MGMT should be detected.\n\n          -  The time to be enrolled should be more than 90 days after the irradiation.\n\n          -  The patients with recurrent gliomas were treated with non-dose-dense TMZ therapy\n             before enrollment.\n\n          -  Performance status(Karnofsky index)>=60\n\n          -  Life expectancy more than 3 months\n\n        Exclusion Criteria:\n\n          -  Ages:< 18 years or > 70 years\n\n          -  Abnormal function of liver or renal(value more than 1.5 fold normal upper limit )\n\n          -  Blood routing: Hb < 100g/l\uff0c WBC \uff1c 4.0\u00d7109/l; PLT < 100\u00d7109/l\n\n          -  Pregnant or lactating women\n\n          -  Allergic to administered drugs\n\n          -  Radiation treatment in the previous 90 days or stereotactic radiation surgery within\n             60 days before enrollment\n\n          -  The patients with recurrent gliomas were treated with dose-dense TMZ therapy before\n             enrollment.\n\n          -  Life expectancy less than 3 months\n\n          -  Participation in other clinical trials in the 90previous days before enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670890", 
            "org_study_id": "pumch-neurosurgery-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "TMZ group", 
                "description": "patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles", 
                "intervention_name": "TMZ", 
                "intervention_type": "Drug", 
                "other_name": "temozolomide"
            }, 
            {
                "arm_group_label": "TMZ plus CDDP group", 
                "description": "patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles", 
                "intervention_name": "TMZ plus CDDP", 
                "intervention_type": "Drug", 
                "other_name": "temozolomide and cisplatin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Temozolomide", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "temozolomide(TMZ)", 
            "cisplatin(CDDP)", 
            "recurrent malignant gliomas"
        ], 
        "lastchanged_date": "August 21, 2012", 
        "location": [
            {
                "contact": {
                    "email": "wangrz@126.com", 
                    "last_name": "wang ren zhi, MD", 
                    "phone": "86-010-69156071"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100730"
                    }, 
                    "name": "Peking Union Medical College Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Ma wen bin, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "wang yu, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jiangtao369@sohu.com", 
                    "last_name": "Jiang tao, MD", 
                    "phone": "86-010-67021832"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100050"
                    }, 
                    "name": "Beijing Tiantan Hospital Affiliated to Capital Medial University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ydenny@yahoo.com", 
                    "last_name": "Yang xue jun, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300052"
                    }, 
                    "name": "Tianjin medical university general university"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Salvage Treatment With Dose-dense TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas: a Multicentre,Prospective Clinical Study", 
        "overall_contact": {
            "email": "wangrz@126.com", 
            "last_name": "wang renzhi, MD", 
            "phone": "86-010-69156071"
        }, 
        "overall_contact_backup": {
            "email": "kingrichwy@126.com", 
            "last_name": "Wang yu, MD", 
            "phone": "86-010-69156071"
        }, 
        "overall_official": {
            "affiliation": "Peking Union Medical College Hospital", 
            "last_name": "wang renzhi, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "over all survival", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670890"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "progression free survival", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Peking Union Medical College Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Beijing Tiantan Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tianjin Medical University General Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Peking Union Medical College Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}